Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

NCT01993186 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Interventions

DRUG: UX007
DRUG: Placebo

Sponsor

Ultragenyx Pharmaceutical Inc